TABLE 1.
The relationship between complications and outcome of patients with COVID-19.
| Complications | Results |
|||
| All(N = 102) | Non-survivors(N = 17) | Survivors(N = 85) | ||
| Cao et al. (46)* | Shock | 10(9.8) | 7(41.1) | 3(3.5) |
| ARDS | 20(19.6) | 15(88.2) | 5(5.9) | |
| Acute infection | 17(16.7) | 14(82.4) | 3(3.5) | |
| Acute cardiac injury | 15(14.7) | 12(70.6) | 3(3.5) | |
| Arrhythmia | 18(17.6) | 12(70.6) | 6(7.1) | |
| Acute kidney injury | 20(19.6) | 15(88.2) | 5(5.9) | |
| Acute liver injury | 34(33.3) | 13(76.5) | 21(24.7) | |
| Lymphopenia | 78(76.5) | 17(100.0) | 61(71.8) | |
| Wang et al. (47)* | All(N = 138) | Non-ICU(N = 102) | ICU(N = 36) | |
| Shock | 12(8.7) | 11(30.6) | 1(1.0) | |
| Acute cardiac injury | 10(7.2) | 8(22.2) | 2(2.0) | |
| Arrhythmia | 23(16.7) | 16(44.4) | 7(6.9) | |
| ARDS | 27(19.6) | 22(61.1) | 5(4.9) | |
| AKI | 5(3.6) | 3(8.3) | 2(2.0) | |
| All(N = 1099) | Non-severe(N = 926) | Severe(N = 173) | ||
| Guan et al. (48)* | Septic shock | 12(1.1) | 1(0.1) | 11(6.4) |
| Acute respiratory distress syndrome | 37(3.4) | 10(1.1) | 27(15.6) | |
| Acute kidney injury | 6(0.5) | 1(0.1) | 5(2.9) | |
| Disseminated intravascular coagulation | 1(0.1) | 0 | 1(0.6) | |
| Rhabdomyolysis | 2(0.2) | 2(0.2) | 0 | |
| Physician-diagnosed pneumonia | 972/1067(91.1) | 800/894(89.5) | 172/173(99.4) | |
| Zhou et al. (49)* | All(N = 191) | Non-survivors(N = 54) | Survivors(N = 137) | |
| Sepsis | 112(59%) | 54(100%) | 58(42%) | |
| Respiratory failure | 103(54%) | 53(98%) | 50(36%) | |
| ARDS | 59(31%) | 50(93%) | 9(7%) | |
| Heart failure | 44(23%) | 28(52%) | 16(12%) | |
| Septic shock | 38(20%) | 38(70%) | 0 | |
| Coagulopathy | 37(19%) | 27(50%) | 10(7%) | |
| Acute cardiac injury | 33(17%) | 32(59%) | 1(1%) | |
| Acute kidney injury | 28(15%) | 27(50%) | 1(1%) | |
| Secondary infection | 28(15%) | 27(50%) | 1(1%) | |
| Hypoproteinemia | 22(12%) | 20(37%) | 2(1%) | |
| Acidosis | 17(9%) | 16(30%) | 1(1%) | |
| Huang et al. (50)* | All(N = 41) | ICU(n = 13) | No ICU care(n = 28) | |
| Acute respiratory distress syndrome | 12(29%) | 11(85%) | 1(4%) | |
| RNAaemia | 6(15%) | 2(15%) | 4(14%) | |
| Cycle threshold of RNAaemia | 35.1(34.7–35.1) | 35.3(35.1–35.1) | 34.8(34.1–35.4) | |
| Acute cardiac injury | 5(12%) | 4(31%) | 1(4%) | |
| Acute kidney injury | 3(7%) | 3(23%) | 0 | |
| Secondary infection | 4(10%) | 4(31%) | 0 | |
| Shock | 3(7%) | 3(23%) | 0 | |
| Chen et al. (51)* | All(N = 33/99) | |||
| ARDS | 17(17%) | |||
| Acute renal injury | 3(3%) | |||
| Acute respiratory injury | 8(8%) | |||
| Septic shock | 4(4%) | |||
| Ventilator-associated pneumonia | 1(1%) | |||
*Reported complications and outcome of patients with COVID-19 from some important studies.